Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apomorphine
Drug ID BADD_D00152
Description Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Indications and Usage For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.
Marketing Status Prescription; Discontinued
ATC Code G04BE07; N04BC07
DrugBank ID DB00714
KEGG ID D07460
MeSH ID D001058
PubChem ID 6005
TTD Drug ID D0H6QU
NDC Product Code Not Available
Synonyms Apomorphine | Apomorphine Hydrochloride, Anhydrous | Apomorphine Hydrochloride Anhydrous | Apomorphine Hydrochloride | Apomorphin-Teclapharm | Apomorphin Teclapharm | Apomorphine Hydrochloride, Hemihydrate | Apokinon | Apomorphine Chloride | Britaject
Chemical Information
Molecular Formula C17H17NO2
CAS Registry Number 58-00-4
SMILES CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionProtein c-FosP01100T2802511070194; 1347413; 7477877
Tremor (excl congenital)Fatty acid-binding protein, adipocyteQ9R290Not Available25933950
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.001273%Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000849%
Agitation19.06.02.001; 17.02.05.0120.001273%
Altered state of consciousness19.07.01.003; 17.02.04.0010.000849%Not Available
Anaemia01.03.02.001--
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.002547%Not Available
Back pain15.03.04.005--
Blood glucose decreased13.02.02.0010.000849%Not Available
Blood pressure decreased13.14.03.0020.001273%Not Available
Bradycardia02.03.02.0020.000849%Not Available
Cardiac arrest02.03.04.0010.000221%
Cardiac failure congestive02.05.01.002--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000221%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.0020.001698%Not Available
Coma17.02.09.0010.000849%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000221%Not Available
Confusional state19.13.01.001; 17.02.03.0050.001698%
Constipation07.02.02.001--
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.0010.001273%
Death08.04.01.0010.002215%
Dehydration14.05.05.001--
Depression19.15.01.0010.001273%
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.004669%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages